EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
U.S. Pharmaceutical Intellectual Property Strategy: Patents, Exclusivity and Competitive Protection
Bringing a new drug to market can cost over a billion dollars and take a decade or more Copying that drug can cost a tiny fraction of that Without legal protection no company could recover its investment and fewer new medicines would reach patients
-
Techno Trends
Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment
Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment
-
Projects
Genentech Begins US$750 Million Expansion of Oregon Manufacturing Facility
Genentech a member of the Roche Group has started construction on a US million expansion of its manufacturing facility in Hillsboro Oregon The squarefoot project will double the existing sites footprint and increase US production capacity for advanced drug delivery devices
-
Research Insights
Identification of flavonoids from natural products against hyperlipidaemia through computational approaches
Over the centuries hyperlipidaemia has been recognised as a major risk factor contributing to cardiovascular disease CVD Current research increasingly explores natural compounds such as flavonoids for their potential lipidlowering effects This study evaluated pharmacological potential
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Alzheimer's Drug Pipeline: Past, Present, and Future Biologic Therapies
Ronny Priefer
Chaehui Sue
The history of Alzheimer’s disease treatment has been fraught with numerous failures, with only a smattering of successes. The rationales for failures are as diverse as the agents and targets th...
-
2
Solutions from Technology to Innovation: Transforming Pharmaceutical Production in North America
Kate Williamson
The integration of technology is reshaping pharmaceutical production in North America, with automation, data analytics, 3D printing, regulatory compliance tools, blockchain, and remote monitoring play...
-
3
Patient-Centric Approaches in Clinical Trials
Vasudev Bhupathi
Patient-centric clinical trials embed participants’ needs at every stage, co-designed protocols, decentralized visits, digital health tools, diversity metrics, and transparent results. This para...
-
4
Next-Generation Immunotherapies: Innovations Beyond CAR-T
Lakshmi
CAR-T therapy validated engineered immunity but left solid tumors, manufacturing complexity and cost largely unsolved. A next wave of immunotherapies — T-cell engagers, in vivo CAR engineering,...
-
5
Uncovering Hidden ERP Implementation Costs Through Life Science Industry Analysis
April Miller
ERP implementation costs in life sciences extend beyond software and consulting fees. Regulatory validation, data migration, system integration, employee training, and operational disruption can signi...
press releasesRead more...
Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
Pfizer Inc announced that the US Food and Drug Administration FDA has expanded approval of TALZENNA talazoparib in combination with XTANDI enzalutamide to the treatment of men with metastatic androgen pathway modulationnave or sensitive mAPMNS prostate cancer PC with homologous recombination repair...
Zef Scientific and Copia Scientific Partner to Deliver Automated Solutions for High-Throughput LC/MS Workflows: “From Sample Prep to LC/MS. Together”
Zef Scientific Inc ZefSci a provider of multivendor liquid chromatographymass spectrometry LCMS service and systems and Copia Scientific a fullservice laboratory automation equipment company today announced a partnership to provide complementary instrumentation workflow support and service for autom...
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Fortrea a leading global contract research organization CRO and Omico Australias leading precision oncology screening and trial matching organization today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarkermatched clinical trials By co...
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Charles River Laboratories International Inc announced a Research Collaboration Agreement RCA with the US Food and Drug Administration FDA and Labcorp for developing sensitive screening tools to quantify and rank the abuse potential of new drugs including abusedeterrent formulations
Events Read more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX Korea
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWSRead more...
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Regeneron Pharmaceuticals Inc announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority BARDA part of the Administration for Strategic Preparedness and Response ASPR within the US Department of Health and Human Services
Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug Delivery
Aptar Pharma a global leader in drug delivery dosing protection technologies and services today announced the strategic acquisition of PULMOTREE a Munich Germanybased life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs The acquisition is expected t...
Ignite Proteomics Enters Breast Cancer Research Collaboration with Leading Cancer Center
Ignite Proteomics Inc a precision oncology company focused on functional proteomics today announced it is collaborating with Memorial Sloan Kettering Cancer Center MSK to study protein signaling patterns associated with treatment response and resistance in advanced breast cancer
Warp Sciences Emerges From Stealth With $215 Million to Build U.S. Chemistry Services for Drug Research
Warp Sciences today emerged from stealth with million in funding to create the infrastructure that enables biotech and pharmaceutical companies to discover new medicines faster The company is building a USbased chemistry contract research organization CRO that brings expert chemists
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck known as MSD outside of the United States and Canada today announced the European Commission EC has approved KEYTRUDA pembrolizumab Mercks antiPD therapy in combination with Padcev enfortumab vedotinejfv as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment...
Verily Health and Autoimmune Registry Partner to Build Cross-Disease Research Infrastructure for Autoimmune Conditions
Verily Health Inc a healthcare data intelligence company today announced a strategic partnership with Autoimmune Registry Inc ARI a nonprofit nominated for the inaugural Prix Galien Patient First Award in Honor of Michael J Fox for its work studying autoimmune diseases the populations they affect a...
